title: Blocking Plasmodium falciparum development via dual inhibition of hemoglobin degradation and the ubiquitin proteasome system by MG132.
abstract: Among key potential drug target proteolytic systems in the malaria parasite Plasmodium falciparum are falcipains, a family of hemoglobin-degrading cysteine proteases, and the ubiquitin proteasomal system (UPS), which has fundamental importance in cellular protein turnover. Inhibition of falcipains blocks parasite development, primarily due to inhibition of hemoglobin degradation that serves as a source of amino acids for parasite growth. Falcipains prefer P2 leucine in substrates and peptides, and their peptidyl inhibitors with leucine at the P2 position show potent antimalarial activity. The peptidyl inhibitor MG132 (Z-Leu-Leu-Leu-CHO) is a widely used proteasome inhibitor, which also has P2 leucine, and has also been shown to inhibit parasite development. However, the antimalarial targets of MG132 are unclear. We investigated whether MG132 blocks malaria parasite development by inhibiting hemoglobin degradation and/or by targeting the UPS. P. falciparum was cultured with inhibitors of the UPS (MG132, epoxomicin, and lactacystin) or falcipains (E64), and parasites were assessed for morphologies, extent of hemoglobin degradation, and accumulation of ubiquitinated proteins. MG132, like E64 and unlike epoxomicin or lactacystin, blocked parasite development, with enlargement of the food vacuole and accumulation of undegraded hemoglobin, indicating inhibition of hemoglobin degradation by MG132, most likely due to inhibition of hemoglobin-degrading falcipain cysteine proteases. Parasites cultured with epoxomicin or MG132 accumulated ubiquitinated proteins to a significantly greater extent than untreated or E64-treated parasites, indicating that MG132 inhibits the parasite UPS as well. Consistent with these findings, MG132 inhibited both cysteine protease and UPS activities present in soluble parasite extracts, and it strongly inhibited recombinant falcipains. MG132 was highly selective for inhibition of P. falciparum (IC50 0.0476 µM) compared to human peripheral blood mononuclear cells (IC50 10.8 µM). Thus, MG132 inhibits two distinct proteolytic systems in P. falciparum, and it may serve as a lead molecule for development of dual-target inhibitors of malaria parasites.
authors.affiliation: CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Andhra Pradesh, India.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Prasad
authors.lastname: Atul
authors.forename: Venkata Karunakar
authors.initials: VK
authors.lastname: Kolla
authors.forename: Jennifer
authors.initials: J
authors.lastname: Legac
authors.forename: Neha
authors.initials: N
authors.lastname: Singhal
authors.forename: Rahul
authors.initials: R
authors.lastname: Navale
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Rosenthal
authors.forename: Puran Singh
authors.initials: PS
authors.lastname: Sijwali
mesh_terms: D003546:Cysteine Endopeptidases / Q000378:metabolism; D004357:Drug Synergism; D004912:Erythrocytes / Q000469:parasitology; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology*; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development* / Q000378:metabolism / Q000502:physiology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D061988:Proteasome Inhibitors / Q000494:pharmacology; D059748:Proteolysis / Q000187:drug effects*; D025801:Ubiquitin / Q000378:metabolism*
chemical_list: D006454:Hemoglobins; D007976:Leupeptins; D061988:Proteasome Inhibitors; D025801:Ubiquitin; D003546:Cysteine Endopeptidases; C099607:falcipain; D046988:Proteasome Endopeptidase Complex; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde
references.citation: Oncol Rep. 2009 Jul;22(1):215-21
references.pmid: 19513526
references.citation: J Biol Chem. 2000 Sep 15;275(37):29000-10
references.pmid: 10887194
references.citation: Antimicrob Agents Chemother. 1998 Sep;42(9):2254-8
references.pmid: 9736544
references.citation: J Biol Chem. 2011 Nov 18;286(46):40320-30
references.pmid: 21930698
references.citation: Neurosci Lett. 1990 Nov 27;120(1):1-4
references.pmid: 2293079
references.citation: Methods Enzymol. 2005;398:364-78
references.pmid: 16275343
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4384-9
references.pmid: 15070727
references.citation: J Neurochem. 1983 Mar;40(3):842-9
references.pmid: 6338156
references.citation: Hum Exp Toxicol. 2010 Jul;29(7):607-14
references.pmid: 20053704
references.citation: J Med Chem. 2013 Jan 10;56(1):31-45
references.pmid: 23270565
references.citation: J Biol Chem. 2006 May 5;281(18):12824-32
references.pmid: 16520377
references.citation: PLoS One. 2012;7(10):e47227
references.pmid: 23077573
references.citation: Nat Struct Biol. 2000 Nov;7(11):1062-7
references.pmid: 11062564
references.citation: J Biol Chem. 2004 Oct 8;279(41):43000-7
references.pmid: 15304495
references.citation: Biochem J. 2004 Mar 1;378(Pt 2):529-38
references.pmid: 14629194
references.citation: PLoS Negl Trop Dis. 2010 Oct 12;4(10):e849
references.pmid: 20967286
references.citation: Int J Parasitol Drugs Drug Resist. 2012 Jan 09;2:1-10
references.pmid: 24533266
references.citation: Malar J. 2008 Sep 24;7:187
references.pmid: 18816382
references.citation: FEMS Microbiol Lett. 2005 Dec 15;253(2):171-84
references.pmid: 16243458
references.citation: Antimicrob Agents Chemother. 2009 Oct;53(10):4080-5
references.pmid: 19651911
references.citation: BMC Clin Pharmacol. 2007 Oct 23;7:13
references.pmid: 17956613
references.citation: Cancer Lett. 2010 Feb 28;288(2):192-203
references.pmid: 19646807
references.citation: J Biol Chem. 1999 Nov 5;274(45):32411-7
references.pmid: 10542284
references.citation: Mol Microbiol. 2007 Jul;65(1):64-75
references.pmid: 17581121
references.citation: J Med Chem. 2010 Aug 26;53(16):6129-52
references.pmid: 20672841
references.citation: J Neurochem. 1980 Nov;35(5):1172-82
references.pmid: 6778972
references.citation: J Biol Chem. 2005 Jan 14;280(2):1432-7
references.pmid: 15513918
references.citation: Antimicrob Agents Chemother. 2003 Dec;47(12):3810-4
references.pmid: 14638488
references.citation: Biochem J. 2006 Oct 1;399(1):47-57
references.pmid: 16776649
references.citation: J Biol Chem. 2011 Aug 5;286(31):27255-65
references.pmid: 21659511
references.citation: Cell. 1998 Feb 6;92(3):367-80
references.pmid: 9476896
references.citation: Genome Res. 2003 Apr;13(4):601-16
references.pmid: 12671001
references.citation: J Parasitol. 1979 Jun;65(3):418-20
references.pmid: 383936
references.citation: Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):990-5
references.pmid: 11782538
references.citation: Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8
references.pmid: 10468620
references.citation: J Biol Chem. 1997 Oct 3;272(40):25200-9
references.pmid: 9312134
references.citation: Genetica. 2009 May;136(1):189-209
references.pmid: 19057851
references.citation: Antimicrob Agents Chemother. 1996 Jul;40(7):1600-3
references.pmid: 8807047
references.citation: Chem Biol. 2012 Jan 27;19(1):99-115
references.pmid: 22284358
references.citation: Antimicrob Agents Chemother. 2003 Jan;47(1):154-60
references.pmid: 12499184
references.citation: Antimicrob Agents Chemother. 2004 May;48(5):1803-6
references.pmid: 15105138
references.citation: Biochem J. 2001 Dec 1;360(Pt 2):481-9
references.pmid: 11716777
references.citation: Adv Exp Med Biol. 2011;712:30-48
references.pmid: 21660657
references.citation: J Biochem. 1996 Mar;119(3):572-6
references.pmid: 8830056
references.citation: Protein Expr Purif. 2001 Jun;22(1):128-34
references.pmid: 11388810
references.citation: J Enzyme Inhib Med Chem. 2009 Feb;24(1):279-86
references.pmid: 18830882
references.citation: Biochem Biophys Res Commun. 1993 Nov 15;196(3):1195-201
references.pmid: 8250877
references.citation: Biochem J. 2002 Nov 15;368(Pt 1):273-81
references.pmid: 12169096
references.citation: Antimicrob Agents Chemother. 1998 Oct;42(10):2731-8
references.pmid: 9756786
references.citation: Nature. 1997 Apr 3;386(6624):463-71
references.pmid: 9087403
references.citation: Parasitology. 2005 Jul;131(Pt 1):37-44
references.pmid: 16038394
references.citation: Mol Biochem Parasitol. 2006 Nov;150(1):96-106
references.pmid: 16890302
references.citation: PLoS One. 2012;7(12):e51619
references.pmid: 23251596
references.citation: Science. 1976 Aug 20;193(4254):673-5
references.pmid: 781840
references.citation: PLoS One. 2009;4(4):e5156
references.pmid: 19357776
references.citation: Oncol Rep. 2011 Jun;25(6):1705-12
references.pmid: 21399877
references.citation: J Clin Invest. 1988 Nov;82(5):1560-6
references.pmid: 3053784